{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:24:06Z","timestamp":1794565446270,"version":"4.9.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009104","name":"Department of Health Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019305","name":"Manipal Academy of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019305","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.diabres.2026.113270","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T06:56:25Z","timestamp":1778136985000},"page":"113270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"237","author":[{"given":"Ramya","family":"Kateel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Parida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharti","family":"Chogtu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-4435","authenticated-orcid":false,"given":"Sadhana N.","family":"Holla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113270_b0005","unstructured":"Lucier J, Mathias PM. Type 1 Diabetes. [Updated 2024 Oct 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507713\/."},{"issue":"10","key":"10.1016\/j.diabres.2026.113270_b0010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.diabres.2026.113270_b0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ecl.2012.03.001","article-title":"Insulin therapy and hypoglycemia","volume":"41","author":"McCall","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"10.1016\/j.diabres.2026.113270_b0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/dom.13052","article-title":"The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes","volume":"20","author":"Gingras","year":"2018","journal-title":"Diabet Obesity Metabol"},{"issue":"8","key":"10.1016\/j.diabres.2026.113270_b0025","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/1060028016651279","article-title":"GLP-1 agonists in type 1 diabetes mellitus","volume":"50","author":"Janzen","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"17","key":"10.1016\/j.diabres.2026.113270_b0030","doi-asserted-by":"crossref","first-page":"9351","DOI":"10.3390\/ijms25179351","article-title":"Mechanistic pathways and clinical implications of GLP-1 receptor agonists in type 1 diabetes management","volume":"25","author":"Delrue","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.diabres.2026.113270_b0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bph.15788","article-title":"New developments in the prospects for GLP-1 therapy","volume":"179","author":"Trapp","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.diabres.2026.113270_b0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/dom.14637","article-title":"Glucagon-like peptide-1 receptor agonists as adjunctive treatment for type 1 diabetes: renewed opportunities through tailored approaches?","volume":"24","author":"Kobayati","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.diabres.2026.113270_b0045","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/dom.13911","article-title":"Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump trial-a randomized, double-blinded, placebo-controlled trial","volume":"22","author":"Dejgaard","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.diabres.2026.113270_b0050","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/dom.12473","article-title":"Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4\u2009weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial","volume":"17","author":"Pieber","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.diabres.2026.113270_b0055","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1111\/dom.15889","article-title":"Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): a randomized, double-blind, placebo-controlled trial","volume":"26","author":"Dejgaard","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.diabres.2026.113270_b0060","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"14","key":"10.1016\/j.diabres.2026.113270_b0065","article-title":"Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus","volume":"16","author":"Tan","year":"2023","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.diabres.2026.113270_b0070","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/dom.14291","article-title":"Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: a systematic review and network meta-analysis","volume":"23","author":"Avgerinos","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113270_b0075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/dom.70188","article-title":"Glucagon-like peptide-1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight\/obesity and type 1 diabetes: a systematic review and meta-analysis","volume":"28","author":"Purcell","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.diabres.2026.113270_b0080","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s13300-017-0282-3","article-title":"Effects of insulin plus glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Diabetes Ther"},{"issue":"3","key":"10.1016\/j.diabres.2026.113270_b0085","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1530\/EC-18-0546","article-title":"Incretin-based therapies for patients with type 1 diabetes: a meta-analysis","volume":"8","author":"Liu","year":"2019","journal-title":"Endocrine Connect"},{"issue":"1","key":"10.1016\/j.diabres.2026.113270_b0090","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/clinem\/dgad471","article-title":"Glucagon-like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: an updated systematic review and meta-analysis","volume":"109","author":"Park","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2026.113270_b0095","article-title":"The PRISMA statement: an updated guideline for reporting systematic reviews","volume":"n71","author":"Page","year":"2020","journal-title":"BMJ"},{"issue":"366","key":"10.1016\/j.diabres.2026.113270_b0100","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"28","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113270_b0105","series-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Webpage on the Internet]","author":"Wells","year":"2011"},{"issue":"4","key":"10.1016\/j.diabres.2026.113270_b0110","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41591-024-03463-z","article-title":"Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial","volume":"31","author":"Pasqua","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.diabres.2026.113270_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101433","article-title":"Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): a randomized double-blind placebo-controlled trial","volume":"49","author":"Thivolet","year":"2023","journal-title":"Diabetes Metab"},{"issue":"9","key":"10.1016\/j.diabres.2026.113270_b0120","doi-asserted-by":"crossref","first-page":"e3583","DOI":"10.1210\/clinem\/dgac369","article-title":"Effect of liraglutide treatment on whole-body glucose fluxes in C-peptide-positive type 1 diabetes during hypoglycemia","volume":"107","author":"Zenz","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.diabres.2026.113270_b0125","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","article-title":"Anti-interleukin-21 antibody and liraglutide for the preservation of \u03b2-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"von Herrath","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.diabres.2026.113270_b0130","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.130","article-title":"Lixisenatide in type 1 diabetes: a randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients","volume":"3","author":"Ballav","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"issue":"11","key":"10.1016\/j.diabres.2026.113270_b0135","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/dom.14121","article-title":"Exenatide extended release in patients with type 1 diabetes with and without residual insulin production","volume":"22","author":"Herold","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.diabres.2026.113270_b0140","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa149","article-title":"Randomized 52-week phase 2 trial of albiglutide versus placebo in adult patients with newly diagnosed type 1 diabetes","volume":"105","author":"Pozzilli","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"10.1016\/j.diabres.2026.113270_b0145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(20)30030-9","article-title":"Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial","volume":"8","author":"Johansen","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.diabres.2026.113270_b0150","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1210\/jc.2019-00087","article-title":"Effect of the GLP-1 receptor agonist exenatide on impaired awareness of hypoglycemia in type 1 diabetes: a randomized controlled trial","volume":"104","author":"van Meijel","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113270_b0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/dom.13063","article-title":"Beyond glycaemic control: a cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes","volume":"20","author":"Dub\u00e9","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.diabres.2026.113270_b0160","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial","volume":"39","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2026.113270_b0165","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc15-1136","article-title":"Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks","volume":"39","author":"Kuhadiya","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2026.113270_b0170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(15)00436-2","article-title":"Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial","volume":"4","author":"Dejgaard","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.diabres.2026.113270_b0175","first-page":"2250","article-title":"Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled","volume":"38","author":"Frandsen","year":"2015","journal-title":"Double-Blind Parallel Study Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2026.113270_b0180","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/1932296814542153","article-title":"Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm","volume":"8","author":"Renukuntla","year":"2014","journal-title":"J Diabetes Sci Technol"},{"issue":"2","key":"10.1016\/j.diabres.2026.113270_b0185","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.diabres.2013.01.020","article-title":"Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study","volume":"100","author":"Hari Kumar","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"10.1016\/j.diabres.2026.113270_b0190","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2337\/dc11-0096","article-title":"Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function","volume":"34","author":"Kielgast","year":"2011","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2026.113270_b0195","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2337\/dc09-1959","article-title":"The role of adjunctive exenatide therapy in pediatric type 1 diabetes","volume":"33","author":"Raman","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113270_b0200","unstructured":"Novo Nordisk. Efficacy and safety of liraglutide in subjects with type 1 diabetes undergoing islet cell transplantation. EU Clinical Trials Register. 2019. Trial ID: EUCTR2009-013090-18-GB."},{"key":"10.1016\/j.diabres.2026.113270_b0205","unstructured":"Novo Nordisk. Study to increase remnant insulin production in patients with type 1 diabetes using liraglutide. EU Clinical Trials Register. 2020. Trial ID: EUCTR2014-005174-11-SE."},{"issue":"14","key":"10.1016\/j.diabres.2026.113270_b0210","article-title":"Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment","volume":"29","author":"Edwards","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.diabres.2026.113270_b0215","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/clinem\/dgac618","article-title":"Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: a real-world study","volume":"108","author":"Edwards","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"Supp 1","key":"10.1016\/j.diabres.2026.113270_b0220","article-title":"Consensus report on glucagon-like peptide-1 receptor agonists as adjunctive treatment for individuals with type 1 diabetes using an automated insulin delivery system","volume":"47","author":"Shah","year":"2024","journal-title":"Diabetes Care"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:22:49Z","timestamp":1794561769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726001890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"alternative-id":["S0168822726001890"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113270","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113270"}}